Table 1: Ten-year survival in relation to various characteristics of patients.
Characteristics | Number | Percentage | Ten-year DFS (%) |
---|---|---|---|
Grading | |||
Good | 101 | 46% | 92 |
Moderate | 64 | 28.8% | 65 |
Poor | 28 | 12.6% | 60 |
Not graded | 28 | 12.6% | 76 |
FIGO Stage 1988 | |||
IA | 102 | 46% | 91 |
IB | 11 | 5% | 67 |
IC | 82 | 36.9% | 72 |
IIA | 23 | 10.4% | 46 |
Risk Group | |||
Low risk IA–IB G1 | 71 | 32% | 91 |
Moderate risk IA–IB G2–G3–GX | 46 | 20.7% | 80 |
High risk IC–IIA | 105 | 47.3% | 62 |
Histological type | |||
Serous | 71 | 32% | 78 |
Mucinous | 63 | 28.4% | 84 |
Endometrioid | 48 | 21.2% | 65 |
Clear cell | 28 | 12.6% | 73 |
Mixed epithelial | 8 | 3.6% | 76 |
Other | 4 | 1.8% | 79 |
Dense adhesions | |||
Yes | 108 | 48.9% | 61 |
No | 114 | 51.1% | 90 |
Peritoneal cytology | |||
Yes | 28 | 12.6% | 43 |
No | 194 | 87.4% | 81 |
Capsule rupture | |||
Yes | 48 | 21.4% | 66 |
No | 174 | 87.4% | 78 |
Age at diagnosis | |||
<54 | 125 | 56.3% | 84 |
>54 | 97 | 43.7% | 66 |
Pre-operatory CA125 | |||
<60 UI/ml | 77 | 54.6% | 85 |
>60 UI/ml | 64 | 45.4% | 76 |
Patients non-IA G1 | |||
Treated with chemotherapy | 113 | 72.9% | 69 |
With taxanes | 45 | 37.8% | 84 |
Without taxanes | 74 | 62.2% | 60 |
Treated without chemotherapy | 42 | 27.1% | 65 |
Lymphoadenectomy in moderate–high risk group | |||
Yes | 41 | 27.1% | 76 |
No | 110 | 72.9% | 62 |
Second look in moderate–high risk group | |||
Yes | 47 | 31.2% | 58 |
No | 104 | 68.8% | 74 |